Endologix, Inc. (NASDAQ:ELGX) Receives Average Rating of “Hold” from Brokerages

Endologix, Inc. (NASDAQ:ELGX) has been given a consensus rating of “Hold” by the seven analysts that are covering the company, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $16.30.

Several equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Endologix from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a research note on Wednesday, August 14th. Royal Bank of Canada set a $7.00 price target on shares of Endologix and gave the stock a “hold” rating in a research note on Friday, August 9th. Finally, ValuEngine raised shares of Endologix from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in shares of Endologix by 8.9% in the fourth quarter. BlackRock Inc. now owns 6,208,597 shares of the medical instruments supplier’s stock worth $4,446,000 after acquiring an additional 509,493 shares during the last quarter. Northern Trust Corp boosted its position in shares of Endologix by 15.9% in the fourth quarter. Northern Trust Corp now owns 1,215,671 shares of the medical instruments supplier’s stock worth $871,000 after acquiring an additional 166,409 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of Endologix by 79.5% in the fourth quarter. Two Sigma Advisers LP now owns 249,082 shares of the medical instruments supplier’s stock worth $178,000 after acquiring an additional 110,300 shares during the last quarter. Deutsche Bank AG boosted its position in shares of Endologix by 121.3% in the fourth quarter. Deutsche Bank AG now owns 433,335 shares of the medical instruments supplier’s stock worth $309,000 after acquiring an additional 237,555 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Endologix by 880.9% in the fourth quarter. Bank of America Corp DE now owns 552,431 shares of the medical instruments supplier’s stock worth $395,000 after acquiring an additional 496,113 shares during the last quarter. 50.46% of the stock is currently owned by institutional investors and hedge funds.

Shares of Endologix stock traded up $0.23 during mid-day trading on Friday, hitting $5.50. 359,368 shares of the stock were exchanged, compared to its average volume of 282,468. Endologix has a twelve month low of $5.15 and a twelve month high of $25.10. The stock has a market capitalization of $97.57 million, a price-to-earnings ratio of -0.76 and a beta of 0.37. The company has a 50-day simple moving average of $6.53 and a 200 day simple moving average of $5.80. The company has a current ratio of 2.53, a quick ratio of 1.80 and a debt-to-equity ratio of 2.45.

Endologix (NASDAQ:ELGX) last released its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.43. Endologix had a negative net margin of 60.32% and a negative return on equity of 120.57%. The company had revenue of $36.24 million for the quarter, compared to analysts’ expectations of $36.09 million. Equities research analysts forecast that Endologix will post -2.69 earnings per share for the current fiscal year.

About Endologix

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

Further Reading: Can individual investors take part in an IPO?

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.